TABLE 3.
Distribution of baseline Candida species by treatment groupa
| Species or source | No. of patients (%)
|
|||
|---|---|---|---|---|
| Anidulafungin dose group (mg)
|
Total | |||
| 50 | 75 | 100 | ||
| C. albicans | 20 (54) | 20 (50) | 22 (56) | 62 (53) |
| C. glabrata | 11 (30) | 10 (25) | 15 (38) | 36 (31) |
| C. parapsilosis | 6 (16) | 4 (10) | 1 (3) | 11 (9) |
| C. tropicalis | 1 (3) | 6 (15) | 3 (8) | 10 (9) |
| C. krusei | 2 (5) | 3 (8) | 0 | 5 (4) |
| Other species | 2 (5) | 0 | 1 (3) | 3 (3) |
| Blood | 36 (97) | 37 (93) | 36 (92) | 109 (94) |
| Tissue | 1 (3) | 7 (18) | 4 (10) | 12 (10) |
| Both | 0 | 4 (10) | 1 (3) | 5 (4) |
a
10 patients had multiple species isolated at baseline. There were 37, 40, and 39 members of the MITT population in the 50-, 75-, and 100-mg groups, respectively (total, 116).